Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

Hong Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2798-2078; OpenAlex author ID A5079175227. Sources: OpenAlex.

Their work

Papers
2 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
5
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 2

  1. Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma. First author DOI 10.1186/s13045-024-01538-5↗
  2. B7-H3 and B7-H4 are independent predictors of a poor prognosis in patients with pancreatic cancer. Co-author DOI 10.3892/ol.2016.4128↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Alan W Long · 1 shared paper, 2024 · strength 0.24
  2. Nai‐Kong V. Cheung · 1 shared paper, 2024 · strength 0.24
  3. Yixiang Mao · 1 shared paper, 2016 · strength 0.06
  4. Wei Li · 1 shared paper, 2016 · strength 0.06
  5. Kai Chen · 1 shared paper, 2016 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.